Our data unveiled a significant enhancement of the production of paracrine growth factors including VEGF, bFGF, HGF, and IGF-1 and a markedly reduction of profibrotic cytokines including TGF-β1 and PDGF in CB2 agonist treated AD-MSCs compared with non-treated AD-MSCs (p < 0.05, Figure 7A-7F ). This evidence concerns the gene CNR2 and Alzheimer disease.